Chris Rabbat will succeed Fabio Cataldi as chief medical officer in Q4 2026, while Tim Kelly was appointed chief technical officer effective immediately.
H1 FY26 financial results
Abivax posted a first-half operating loss of EUR 140.3 million, widening 49.73% year over year.
Net loss widened 64.58% to EUR 165.9 million, while operating income edged up 19.05% to EUR 2.5 million.
R&D costs climbed 38.38% to EUR 107.9 million, and G&A expenses rose 86.5% to EUR 30.4 million.
Sales and marketing spend more than doubled to EUR 4.6 million, and cash, cash equivalents and short-term investments totaled EUR 402.4 million at June 30.
ABVX•
